XML 61 R44.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Acquisition of Ascyrus (Details) $ in Thousands |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Sep. 02, 2020 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2024 USD ($) item | Dec. 31, 2023 USD ($)
Business Acquisition [Line Items] |  |  |  |
Noncurrent portion of contingent consideration |  |  | $ 52,880 | $ 63,890
Ascyrus Medical LLC |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Equity ownership percent | 100.00% |  |  |
Cash consideration | $ 60,000 |  |  |
Common stock value issued in business combination | 20,000 |  |  |
Contingent consideration, fair value adjustment |  |  | 11,000 | 23,500
Noncurrent portion of contingent consideration |  |  | $ 52,900 | $ 63,900
Ascyrus Medical LLC | Measurement Input, Discount Rate |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Contingent consideration, measurement input | item |  |  | 0.17 |
Ascyrus Medical LLC | Maximum |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Aggregate amount of consideration transferred | 200,000 |  |  |
Ascyrus Medical LLC | FDA Approval IDE for AMDS |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | 10,000 | $ 10,000 |  |
Common stock value issued in business combination | 10,000 | $ 10,000 |  |
Ascyrus Medical LLC | FDA Approval PMA for AMDS |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | 25,000 |  |  |
Ascyrus Medical LLC | AMDS Obtained In Japan |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | 10,000 |  |  |
Ascyrus Medical LLC | AMDS Obtained In China |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | 10,000 |  |  |
Ascyrus Medical LLC | Additional Potential Cash Payment If Japan Or China Obtains Approval |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | 55,000 |  |  |
Ascyrus Medical LLC | Additional Potential Cash Payment If Japan Or China Obtains Approval | Maximum |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | 75,000 |  |  |
Ascyrus Medical LLC | Additional Potential Cash Payment If Japan Or China Obtains Approval | Minimum |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Cash consideration | $ 65,000 |  |  |
Ascyrus Medical LLC | Following FDA Approval For AMDS |  |  |  |
Business Acquisition [Line Items] |  |  |  |
Aggregate amount of consideration transferred |  |  | $ 100,000 |
Period of required contingent consideration | 3 years |  |  |

X
- Definition Business Combination, Contingent Consideration, Period + References No definition available. + Details
Name: | aort_BusinessCombinationContingentConsiderationPeriod
Namespace Prefix: | aort_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent Consideration, Fair Value Adjustment + References No definition available. + Details
Name: | aort_ContingentConsiderationFairValueAdjustment
Namespace Prefix: | aort_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of input used to measure contingent consideration liability from business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=aort_AscyrusMedicalLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_FdaApprovalIdeForAmdsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_FDAApprovalPMAForAMDSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_AmdsObtainedInJapanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_AmdsObtainedInChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_AdditionalPotentialCashPaymentIfJapanOrChinaObtainsApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=aort_FollowingFdaApprovalForAmdsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |